Prospects of using pancragen for correction of metabolic disorders in elderly people
Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA, Bondarenko EV · 2011 · Bulletin of experimental biology and medicine 151(4):454-456. PMID 22448364
What does this source report?
Reports glucose, insulin and insulin-resistance measures in older patients, including comparison with patients not receiving Pancragen.
- Population and setting
- 30 healthy older people and 33 older people with type-2 diabetes
- Evidence type
- Human comparative study
- Preparation
- Synthetic peptide / defined-sequence research
- Source language
- English abstract; see original for language
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- The 30 healthy participants are not established as a randomized treatment-control arm; treated subgroup sizes, blinding and allocation require full methods.
- Full methods, adverse-event reporting and independent replication remain to be appraised.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Europe PMC indexed citation and abstract checked. Full original paper not reviewed.
Recorded source-check date: 2026-09-30. This date does not imply a completed systematic review.
Source provenance: Journal publication
Cite and trace this record
Original source: Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA, Bondarenko EV. Prospects of using pancragen for correction of metabolic disorders in elderly people Bulletin of experimental biology and medicine 151(4):454-456. PMID 22448364 2011.
Molekul research summary: https://molekul.io/research/kh-22448364. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry